Bone Health

Immunology

Hematology

Respiratory

Dermatology

Diabetes

Gastroenterology

Neurology

Oncology

Ophthalmology

Rare Disease

Rheumatology

News

All News

Product Approvals and Launches

Media

All Videos

Insights

Interviews

Peer Exchange

Podcasts

Stakeholder Summit

Conferences

Conference Coverage

Conference Listing

CME/CE

Resources

Authors

Biosimilar Resources

Interactive Tools

Partners

Polls and Quizzes

WHEN CHOICE ARRIVES: Competition & Consequences

Subscribe

BIOSIMILAR APPROVALS

Skylar Jeremias is the Managing Editor for The Center for Biosimilars and The American Journal of Managed Care (AJMC).

Articles

A commentary on Irish oncology spending finds hospital drug costs rose more than 3100% in under a decade, while biosimilar uptake remained low.

Irish Oncology Drug Costs Rose Over 3100% as Biosimilar Uptake Lagged

Panelists at an IGBA Global Biosimilars Week webinar detailed worldwide access gains and adoption barriers.

IGBA's Global Biosimilars Week Panel Spotlights Value of Access

Laura Joszt, MA, is the vice president of content for the managed care and pharmacy brands at MJH Life Sciences

. She has been with MJH Life Sciences since 2011.

Laura has an MA in business and economic reporting from New York University.

Biosimilar market share averaged 40.7% across 27 European countries by mid-2024, with gain-sharing, switching, and quotas linked to higher uptake.

Biosimilar Uptake in Europe Reached 40.7%, With Wide Country Gaps

Highest biosimilar uptake occurred where policymakers combined multiple supply- and demand-side measures or ran coordinated national tendering.

National Tendering, Combined Policies Linked to Highest Biosimilar Uptake

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and emerging treatment paradigms.

About

Contact

Advisory Board

Do Not Sell My Information

Terms & Conditions

Privacy Policy

The Center for Biosimilars - Biosimilars, Health Economics & Insights

Facebook

Twitter

LinkedIn

Business Practice

Business

Development

Legal

Policy

Practice

Regulatory

The Center for Biosimilars
259 Prospect Plains Road, Building H
Cranbury, NJ 08512-3712

---------------------------------------------------

1rem

Contact Us

Contact Us

The Center for Biosimilars259 Prospect Plains Road, Building HCranbury, NJ 08512-3712

---------------------------------------------------

Editorial Staff

The Center for Biosimilars
259 Prospect Plains Road, Building H
Cranbury, NJ 08512-3712